

# Defect in Negative Selection in *lpr* Donor-derived T Cells Differentiating in Non-*lpr* Host Thymus

By Koji Matsumoto, Yasunobu Yoshikai, Taiji Asano,  
Kunisuke Himeno, Akinori Iwasaki, and Kikuo Nomoto

From the Department of Immunology, Medical Institute of Bioregulation,  
Kyushu University, Fukuoka 812, Japan

## Summary

Transplantation of bone marrow cells of *lpr/lpr* mice into irradiated normal mice fails to develop massive lymphadenopathy or autoimmunity but causes severe graft-vs.-host-like syndrome. To elucidate an abnormality of *lpr/lpr* bone marrow-derived T cells, we transplanted bone marrow cells of Mls<sup>b</sup> *lpr/lpr* mice into H-2-compatible Mls<sup>a</sup> non-*lpr* mice. Although *lpr/lpr* T cell precursors repopulated the host thymus as well as +/+ cells, a proportion of CD4<sup>+</sup>CD8<sup>+</sup> cells decreased, and that of both CD4<sup>-</sup> and CD8<sup>-</sup> single-positive cells increased compared with those of +/+ recipients. Notably, in MRL/*lpr* → AKR and C3H/*lpr* → AKR chimeras, CD4 single-positive thymocytes contained an increased number of Vβ6<sup>+</sup> cells in spite of potentially deleting alleles of Mls<sup>a</sup>, whereas Vβ6<sup>+</sup> mature T cells were deleted in the MRL/+ → AKR and C3H/+ → AKR chimeras. There was no difference between MRL/+ → AKR and MRL/*lpr* → AKR chimeras in their proportion of Vβ3<sup>+</sup> cells because both host and donor strain lack the deleting alleles. Interleukin 2 receptor expression of mature T cells, in the thymus and lymph node, was obviously higher in the MRL/*lpr* → AKR chimeras, in particular in the “forbidden” Vβ6<sup>+</sup> subset. Moreover, *lpr* donor-derived peripheral T cells showed vigorous anti-CD3 response. These results indicate that *lpr*-derived T cells escape not only tolerance-related clonal deletion but also some induction of unresponsiveness in the non-*lpr* thymus.

Mice homozygous for the *lpr* gene spontaneously develop a massive T cell proliferation and an autoimmune syndrome with age (1, 2). The bulk of evidence favors the view that an essential abnormality in *lpr* mice presents in T cell lineage. The major population of cells accumulating in the lymphoid tissue is a unique subset of Thy-1<sup>+</sup>, L3T4<sup>-</sup>, Lyt-2<sup>-</sup>, B220<sup>+</sup>, and Pgp-1<sup>+</sup> (3–5). They seem to belong to a T cell lineage in consideration for expression of TCR-α/β (6), albeit at low density, lack of Ig gene rearrangements (4), and generation in the thymus (7). Neonatal thymectomy reduces lymphadenopathy and autoimmune syndrome (8, 9). Thymus grafting into neonatally thymectomized *lpr* mice causes recurrence of lymphoproliferation, irrespective of thymic genotype (10). Transplantation of normal bone marrow (BM)<sup>1</sup> into *lpr* mice prevents the development of the disease (11, 12). Non-*lpr* BM cells transferred into *lpr* mice with Thy-1-congenic *lpr* BM do not contribute to form accumulating B220<sup>+</sup> CD4<sup>-</sup>CD8<sup>-</sup> T cells (13). These phenomena suggest an importance of the existence of the thymus for development of the disease and an intrinsic abnormality in *lpr* stem cells.

Transplantation of *lpr* BM cells into irradiated normal mice fails to develop massive lymphadenopathy or autoimmunity but causes severe wasting syndrome (11, 14, 15), i.e., loss of body weight, progressive fibrosis, and cellular depletion of lymphoid tissue (14). Although the syndrome resembles subacute GVHD, transplantation of T cell-depleted BM cells or fetal liver cells does not prevent the GVHD-like syndrome (14). The cellular basis of the *lpr*-associated GVHD remains unknown. Supposing that this *lpr*-associated wasting syndrome is also mediated by T cell lineage, the effector T cells must be generated in the host thymus. As for radiation BM chimeras, injected donor-derived T cell precursors colonize the host thymus and proliferate under the influence of the thymic environment, resulting in undergoing thymic selection, which includes clonal deletion (16, 17).

To investigate intrathymic selection of *lpr* BM-derived T cells, we transplanted BM cells of Mls<sup>b</sup> *lpr/lpr* mice into H-2-compatible Mls<sup>a</sup> non-*lpr* mice. Here, we show that *lpr*-derived T cells escape clonal deletion in the non-*lpr* thymus and that, from data of IL-2R expression and proliferative response, they are highly activated in vivo. The implications of these findings for a mechanism of self-tolerance and a relationship to subsequent manifestation of wasting syndrome in the *lpr* → non-*lpr* chimeras are discussed.

<sup>1</sup> Abbreviation used in this paper: BM, bone marrow.

## Materials and Methods

**Mice.** Female AKR/JSea(AKR, H-2<sup>k</sup>, Thy-1.1, Mls<sup>a</sup>/Mls-1<sup>b2b</sup>) mice and MRL/Mp-*lpr/lpr*(MRL/*lpr*, H-2<sup>k</sup>, Thy-1.2, Mls<sup>b</sup>/Mls-1<sup>b2b</sup>) mice were obtained from Seiwa Experimental Animals (Nakatsu, Japan). Female C3H/He(C3H/+, H-2<sup>k</sup>, Thy-1.2, Mls<sup>c</sup>/Mls-1<sup>b2a</sup>) and female C57BL/6(B6, H-2<sup>b</sup>, Thy-1.2, Mls<sup>b</sup>/Mls-1<sup>b2b</sup>) mice were from the Japan SLC Inc. (Hamamatsu, Shizuoka, Japan). Breeding pairs of MRL/Mp-+/+(MRL/+, H-2<sup>k</sup>, Thy-1.2, Mls<sup>b</sup>/Mls-1<sup>b2b</sup>) and C3H/HeJ-*lpr/lpr*(C3H/*lpr*, H-2<sup>k</sup>, Thy-1.2, Mls<sup>c</sup>/Mls-1<sup>b2a</sup>) mice were obtained from The Jackson Laboratory (Bar Harbor, ME) and maintained under a specific pathogen-free condition at our institute.

**Chimeras.** 8-wk-old AKR mice, or C3H mice in some experiments, were lethally irradiated (950 rad, <sup>60</sup>Co source), and 6 h later, these mice were reconstituted with  $5 \times 10^6$  bone marrow cells from 8-wk-old MRL/*lpr*, C3H/*lpr*, and their +/+ controls. The BM cells were treated with anti-CD4(GK1.5) and anti-CD8 mAbs (anti-mouse Lyt-2.1 or Lyt-2.2; Meiji Institute of Health Science, Tokyo) and complement, then were washed three times with Hanks' balanced solution before reconstitution.

**Preparation of T Cells.** Thymocytes were purified according to the panning method as previously described (18). Cell suspensions were poured onto anti-Thy-1.1 mAb (Meiji Institute of Health Science)-coated dishes. After incubation for 70 min at 4°C, nonadherent cells were removed and the bound cells were recovered by flushing. After two cycles of selection, >97% of the recovered cells were Thy-1.1<sup>+</sup> or Thy-1.2<sup>+</sup> cells. In some experiments, Thy-1.2<sup>+</sup> cells were further separated into CD8<sup>-</sup> and CD8<sup>+</sup> cells using anti-CD8 mAb-coated dishes. LN cells were aseptically obtained from axillary, inguinal, and mesenteric nodes and were suspended in RPMI 1640 supplemented with 10% heat-inactivated FCS. The cells were treated with anti-Thy-1.1 mAb plus complement to remove radioresistant host-derived T cells.

**Flow Microfluorometry.** FITC-conjugated anti-Thy-1.2, PE-conjugated anti-CD4 mAb and FITC-conjugated anti-CD8 mAb were purchased from Becton Dickinson & Co. (Oxnard, CA). The hybridoma secreting anti-CD3 mAb (clone 145-2C11) was grown *in vitro*, and the supernatant was precipitated by ammonium sulfate and was purified through a protein A column. Purified anti-CD3 mAb was conjugated with FITC in our laboratory. Undiluted culture supernatant of rat hybridoma, 44-22-1, was used as a mAb that recognizes all TCRs using V $\beta$ 6 gene segments (19) followed by FITC-conjugated goat anti-rat IgG (Tago Inc., Burlingame, CA). mAb KJ16-133, which recognizes TCRs using products of the V $\beta$ 8 gene family (V $\beta$ 8.1/8.2; 20) was also used. Culture supernatant of hamster hybridoma, KJ25, was used as a mAb that recognizes all TCRs using V $\beta$ 3 gene segments (21) followed by FITC-conjugated goat anti-hamster IgG (Tago Inc.). Anti-IL-2R mAb was purified from culture supernatant of 7D4 (22) by separation with HPLC and was biotinylated in our laboratory. To stain CD4 vs. TCR V $\beta$ , 10<sup>6</sup> cells were incubated with anti-V $\beta$  supernatant first, FITC-conjugated anti-rat (mouse) IgG second, and then followed by PE-conjugated anti-CD4 mAb for 40 min for each staining at 4°C. For staining IL-2R vs. TCR V $\beta$ , first and second FITC stainings were followed by biotinylated anti-IL-2R- $\alpha$  (7D4) mAb and PE-streptavidin. In V $\beta$ 6 and V $\beta$ 8 staining, samples were incubated with twice-diluted rat serum after FITC-conjugated anti-rat IgG staining to block unoccupied binding sites. All samples were treated with ammonium chloride to remove erythrocytes and analyzed on FACScan or FACS440 flow cytometer (Becton Dickinson & Co.). Dead cells and debris were excluded from analysis by selective gating based on anterior and right angle scatter. In most experiments,  $5 \times 10^4$  flow cytometer events were analyzed, using Consort 30 software. All data were collected and displayed


on a log scale of increasing green and red fluorescence intensity. Data were presented as two-dimensional contour maps or histograms. To obtain percentages of the thymocyte subpopulations, total counts were integrated in selected areas of the contour plots. IL-2R expression on T cell subpopulations was determined by software gating using one staining parameter (CD3, V $\beta$ 6, V $\beta$ 3, Thy-1.2).

**In Vitro Proliferation Assay.** Cells were cultured in 96-well, flat-bottomed microtiter plates (Costar, Cambridge, MA) with a volume of 200  $\mu$ l RPMI 1640 supplemented with 10% nu serum, 10 mM HEPES, 2 mM L-glutamine,  $5 \times 10^{-5}$  M 2-ME, and 50  $\mu$ g Kanamycin. Anti-CD3 mAb was added at various concentrations. 10<sup>6</sup> cells were distributed into each well. After 48 h of incubation at 37°C in 5% CO<sub>2</sub>, cultures were pulsed with [<sup>3</sup>H]thymidine for an additional 18 h. The cells from individual wells were then collected on filter papers with an automatic harvester and assayed for radioactivity in a liquid scintillation counter.


## Results

**Regeneration and Replacement of Thymocytes in Whole Body-irradiated BM Chimeras.** Recipient AKR mice (H-2<sup>k</sup>, Thy-1.1, Mls<sup>a</sup>) were lethally irradiated and reconstituted with marrow cells from *lpr* mice of MRL (H-2<sup>k</sup>, Thy-1.2, Mls<sup>b</sup>) or C3H (H-2<sup>k</sup>, Thy-1.2, Mls<sup>c</sup>) strains. Thymocytes from the recipients were serially harvested, counted, and stained with FITC-conjugated anti-Thy-1.2. As shown in Fig. 1, the total cell numbers in the thymus decreased to the lowest value on day 7 after reconstitution and then increased exponentially. Host Thy-1.1<sup>+</sup> thymocytes were almost completely replaced by Thy-1.2<sup>+</sup> cells by day 21 after BM transplantation. T cell precursors derived from *lpr* mice repopulated the host thymus as well as normal mice-derived cells did. However, in recipients of *lpr* BM cells, total cell number of thymocytes gradually declined after complete replacement of the thymus, while that in recipients of +/+ BM cells recovered to the original volume before irradiation.

Subsequent analysis on CD4 and CD8 expression of the thymocytes revealed an unusual pattern of differentiation of *lpr*-derived cells. Thy-1.2-positive (donor-derived) cells were purified from whole thymocytes by the panning method. Fig. 2 demonstrates sequential appearance of expression of the donor-derived thymocytes at the early stage of BM transplantation. On days 14 and 21, a relatively early stage, there is no difference between MRL/+  $\rightarrow$  AKR and MRL/*lpr*  $\rightarrow$  AKR chimeras. On and after day 28, in MRL/*lpr*  $\rightarrow$  AKR, a proportion of the double-positive (CD4<sup>+</sup>CD8<sup>+</sup>) subset decreased, and that of the single-positive (both CD4<sup>+</sup>CD8<sup>-</sup> and CD4<sup>-</sup>CD8<sup>+</sup>) cells became higher. Taking the decrease of total cell number into consideration, that change in the ratio of each subset may be mainly attributed to a decrease of the number of double-positive cells, which seems to be a precursor of the mature T cell and the critical stage of intrathymic negative selection process (23, 24). However, *lpr* BM-derived T cell precursors colonized, proliferated, and differentiated in the host thymus and consequently gave rise to "mature-type" single-positive cells as well as control BM-derived T precursors did. Most of single-positive thymocytes that appeared in the MRL/*lpr*  $\rightarrow$  AKR and MRL/+  $\rightarrow$  AKR chimeras expressed a high intensity of CD3 after day 28 (data not shown).



**Figure 1.** Regeneration of thymocytes in the thymus of the irradiated host mice. (□) Total cell count of the thymus; (■) cell count of donor-derived (Thy-1.2<sup>+</sup>) thymocytes: (total cell count) × (percentage of Thy-1.2<sup>+</sup> cells/100). Each point represents the mean value of three to five samples.



**Figure 2.** Expression of CD4 and CD8 by donor-derived thymocytes on day 14 (a and b), day 21 (c and d), and day 35 (e and f). Samples were obtained from MRL/+ → AKR chimeras (a, c, and e) and MRL/lpr → AKR chimeras (b, d, and f). Host-derived radioresistant thymocytes were removed by the panning method, as described in Materials and Methods. All the applied samples were >98% Thy-1.2<sup>+</sup>.

**TCR Expression of CD4 Single-positive Thymocytes.** In the thymus of Mls<sup>a</sup> mice, Vβ6<sup>+</sup> cells are selectively deleted in mature (CD4<sup>+</sup>CD8<sup>-</sup>CD3<sup>+</sup> or CD4<sup>-</sup>CD8<sup>+</sup>CD3<sup>+</sup>) subsets (19, 25). Further, Vβ6<sup>+</sup> cells are also deleted in Mls<sup>b</sup> → Mls<sup>a</sup> radiation chimeras (26), even at the early stage (27) of BM transplantation. The analysis of clonal deletion of Vβ6<sup>+</sup> and Vβ8.1<sup>+</sup> cells in Mls<sup>a</sup> mice indicated that class II-expressing cells might be involved in the deletion process (19, 26, 28), thereby, we investigated an expression of several TCR Vβ on CD4 single-positive thymocytes in order to estimate clonal deletion in the thymus of (Mls<sup>b</sup>,lpr) → (Mls<sup>a</sup>,non-lpr) chimeras. Results from analysis on CD8-depleted thymocytes on days 28–42 were summarized in Table 1, and typical data were presented in Fig. 3. Notably, CD4 single-positive thymocytes from lpr/lpr → AKR chimeras contained an appreciate number of Vβ6<sup>+</sup> cells (Fig. 3, e and k). On the other hand, in the +/+ recipients, CD4 single-positive thymocytes did not contain Vβ6<sup>+</sup> cells because of probable clonal deletion in the Mls<sup>a</sup> host thymus. In the case of MRL → AKR chimeras, there was no difference between lpr/lpr and +/+ recipients in proportion of Vβ3<sup>+</sup> cells (Fig. 3, c and f), which are deleted in neither host nor donor strain. A frequency of KJ16<sup>+</sup> cell was higher in C3H/lpr → AKR chimeras (l) compared with that in C3H/+ → AKR chimeras (i) probably due to the frequency of Vβ8.1<sup>+</sup> cells.

Two possibilities could be brought forward to explain this finding. (a) T cells derived from lpr BM are unusual in being not subjected to clonal deletion; and (b) APC from lpr BM appeared in the thymus to have a defect in tolerance-related antigen presenting ability. To investigate these possibilities, we constructed mixed chimeras that were transplanted with mixture of BM cells from MRL/lpr and AKR. The (MRL/lpr

**Table 1.** *lpr* Mice-derived  $V\beta 6^+ CD4^+ CD8^-$  Thymocytes Escape Clonal Deletion in Irradiated *Mls-1<sup>a</sup>* Hosts

	Percent $V\beta 6^+$ at:			Percent $V\beta 3^+$ at:		
	4 wk	5 wk	6 wk	4 wk	5 wk	6 wk
MRL/+ $\rightarrow$ AKR	0.78 (0.22)	0.76 (0.07)	0.73 (0.20)	ND	6.96 (0.71)	6.62 (0.55)
MRL/ <i>lpr</i> $\rightarrow$ AKR	3.70 (0.70)	3.02 (0.11)	2.81 (0.99)	ND	6.67 (0.13)	7.45 (0.86)
C3H/+ $\rightarrow$ AKR	1.20 (0.24)	1.16 (0.38)	0.73 (0.31)	ND	ND	ND
C3H/ <i>lpr</i> $\rightarrow$ AKR	4.66 (0.83)	2.73 (0.81)	1.61 (0.15)	ND	ND	ND
MRL/+ ,AKR $\rightarrow$ AKR*	1.96 (0.08)	ND	1.43 (0.71)	ND	ND	6.48 (0.51)
MRL/ <i>lpr</i> ,AKR $\rightarrow$ AKR†	1.58 (0.26)	ND	1.65 (0.99)	ND	ND	5.79 (0.96)
MRL/+ $\rightarrow$ C3H	8.84 (0.34)	8.62 (0.48)	ND	1.36 (0.42)	1.67 (0.60)	ND
MRL/ <i>lpr</i> $\rightarrow$ C3H	9.08 (0.25)	8.00 (0.33)	ND	2.08 (0.64)	1.79 (0.96)	ND

The values represent  $V\beta^+$  percentage in  $CD4^+ CD8^-$  cells. Five to six mice were examined and the mean value ( $\pm$  SEM) is given.

\* Lethally irradiated AKR mice were reconstituted with  $4 \times 10^6$  BM cells from MRL and the same number of cells from AKR. Percent Thy-1.2 of recovered thymocytes was  $27.8 \pm 4.3$  (4 wk) and  $22.0 \pm 11.3$  (6 wk). Cells were then depleted of Thy-1.1<sup>+</sup> cells by the panning method and purified to  $>98\%$  Thy-1.2<sup>+</sup>.

† Percent Thy-1.2 of initially recovered thymocytes was  $53.1 \pm 10.0$  (4 wk) and  $24.8 \pm 11.1$  (6 wk).


+ AKR)  $\rightarrow$  AKR chimeras showed complete deletion of *lpr*-derived (Thy-1.2<sup>+</sup>)  $V\beta 6^+$  mature thymocytes (Table 1), suggesting that normal *Mls<sup>a</sup>* APC have an ability to induce clonal deletion to *lpr*-derived T cells, and that *lpr*-BM derived T cells can be subjected to clonal deletion. However, weight loss and lymphoid atrophy were also observed in (MRL/*lpr* + AKR)  $\rightarrow$  AKR chimeras, indicating that mere defect in clonal deletion is not sufficient to explain *lpr*-associated GVHD.

Next, to determine whether failure to delete  $V\beta 6$  is unique or representative of a generalized failure to delete self-reactive T cells, the MRL  $\rightarrow$  C3H(*Mls<sup>c</sup>*) chimeric combination was investigated. As shown in Table 1, no significant difference was seen between MRL/*lpr*  $\rightarrow$  C3H and MRL/+  $\rightarrow$  C3H chimeras in  $V\beta 3$  expression. Relatively fewer  $V\beta 3^+$  cells made it difficult to analyze. It is not likely that  $V\beta 6^+$  T cells preferentially contribute to *lpr* GVHD because expression of  $V\beta 6$  was not significantly elevated in *lpr*  $\rightarrow$  C3H compared with +/+  $\rightarrow$  C3H. Wasting appearance and fibrosis of the spleen were not so severe in MRL/*lpr*  $\rightarrow$  C3H as in MRL/*lpr*  $\rightarrow$  AKR chimeras.

*Spontaneous Activation of lpr-derived T Cells.* If "forbidden" T cells, which are able to recognize and respond to self-antigen,

exist in the thymus of *lpr* recipients, they should be receiving an intense, continuous stimulation. To confirm a degree of activation of T cells in the MRL/*lpr*  $\rightarrow$  AKR chimeras, we assessed an expression of IL-2R on each particular  $V\beta$  subset using anti-Tac mAb (22, 29). Assays were carried out on day 35 after BM transplantation. Representative data are shown in Fig. 4.  $V\beta 6^+ CD4^+ CD8^-$  thymocytes were deleted in MRL/+  $\rightarrow$  AKR (a) and appeared in MRL/*lpr*  $\rightarrow$  AKR (b), C57BL/6 (IE<sup>-</sup>)  $\rightarrow$  AKR (c), and MRL/*lpr*  $\rightarrow$  C3H (d) chimeras. Particularly in the "forbidden"  $V\beta 6^+$  subset, which was seen in *lpr*  $\rightarrow$  AKR chimeras (e), IL-2R expression was nearly three times higher than *lpr*  $\rightarrow$  C3H chimeras (g). Although B6(I-E<sup>-</sup>)  $\rightarrow$  AKR chimeras also allow an appearance of  $V\beta 6^+$  cells, IL-2R expression of  $CD4^+ V\beta 6^+$  thymocytes in this combination is not increased (Fig. 4 f), as reported on SJL(H-2<sup>s</sup>)  $\rightarrow$  B6  $\times$  CBA/J chimeras (30), and is virtually equivalent to that of untreated young MRL/*lpr* mice and MRL/+ mice (data not shown). The  $V\beta 3^+$  subset seen in *lpr*  $\rightarrow$  AKR chimeras also contained more IL-2R<sup>+</sup> cells (Fig. 4 m) than MRL/+  $\rightarrow$  AKR chimeras (l), but less than the  $V\beta 6^+$  subset of the identical individuals. Incidence of IL-2R<sup>+</sup> cells in  $CD3^{\text{high}}$  thymocytes (p) and peripheral donor-derived (Thy-1.2<sup>+</sup>) T cells of MRL/*lpr*  $\rightarrow$  AKR

CD8-depleted thymocytes



**Figure 3.** Expression of TCR Vβ6 (a, b, d, e, g, h, j, and k), Vβ3 (c and f), and Vβ8 (i and l). Samples were obtained from 8-wk-old untreated mice (a, d, g, and j), MRL/+ → AKR (b and c), MRL/lpr → AKR (e and f), C3H/+ → AKR (h and i), and C3H/lpr → AKR chimeras (k and l). CD8<sup>+</sup> cells were depleted by the panning method using anti-Lyt-2.1-coated dishes. Nonadherent cells were stained and analyzed by two-color flow cytometry. Data represent one of the five mice tested. The other four showed similar staining patterns in each panel. All the applied samples were >99% Thy-1.2<sup>+</sup> and contained <2% CD8<sup>+</sup> cells. The value in each figure represents FL1-positive percentage in FL2(CD4)-positive cells (quadrant 1/quadrant 1 + quadrant 2).


chimeras (t) was higher than those of MRL/+ → AKR chimeras (o and s). In MRL/lpr → C3H, IL-2R expression was slightly increased in CD3<sup>high</sup> thymocytes and was twice increased in Thy-1.2<sup>+</sup> LN cells compared with its control (not shown), however, less apparent than in the MRL → AKR combinations.

In lpr → non-lpr chimeras, cell numbers in lymphoid tissue gradually decreased to <1% of that in control chimeras by day 70 after BM transplantation (14; and our data). To estimate a proliferative capacity of lpr-derived surviving T cells, we investigated in vitro response to anti-CD3 mAb on day 35, that is, before complete lymphoid atrophy. LN cells from chimeras were treated with anti-Thy-1.1 mAb plus comple-

ment to remove radioresistant host-derived T cells. As shown in Table 2, donor-derived T cells from MRL/lpr → AKR chimeras virtually exhibited spontaneous proliferation without stimulation and an unusual high but dose-dependent response to anti-CD3 mAb; it is compatible with increased IL-2R expression of peripheral T cells. Taken together, these results suggest in vivo activation of lpr-derived T cells that have differentiated in the host thymus.

### Discussion

Generally, in radiation BM chimeras, donor-derived T cell precursors that colonize the host thymus proliferate exponen-



**Figure 4.** IL-2R expression on various T cell subsets (*e-v*). CD8-depleted thymocytes (*a-n*) were set gate on  $V\beta 6^{\text{high}}$  (*e-g*),  $V\beta 8^{\text{high}}$  (*h-k*), and  $V\beta 3^{\text{high}}$  (*i-n*). Whole thymocytes are set gate on  $CD3^{\text{high}}$  (*o-r*). LN cells are set gate on  $\text{Thy-1.2}^+$  (*s-v*). Samples were obtained from MRL/+  $\rightarrow$  AKR (*a, h, l, o, and s*), MRL/*lpr*  $\rightarrow$  AKR (*b, e, i, m, p, and t*), C57BL/6  $\rightarrow$  AKR (*c, f, j, n, q, and u*), and MRL/*lpr*  $\rightarrow$  C3H chimera (*d, g, k, r, and v*). CD8-depleted samples (*a-n*) contained <2%  $CD8^+$  cells. Most (85–90%) of  $CD3^{\text{high}}$  thymocytes were CD4 or CD8 single positive, and the remaining cells were mainly  $CD4^+CD8^+$  cells. Data represent one of the five mice tested. All the other four showed similar staining patterns in each panel.

tially in the thymic environment and then undergo a thymic education including clonal deletion of self-reactive cells. Donor BM-derived mature T cells, emigrating from the thymus, come to get unresponsiveness to the host antigens even in fully allogeneic combinations (16). However, results from *lpr*  $\rightarrow$  non-*lpr* chimeras do not seem to be consistent with this accepted view on BM chimeras. We have detected a “forbidden”  $V\beta 6^+$  clone in the thymus of AKR ( $Mls^a$ ) reconstituted with BM of H-2-compatible  $Mls^b$  *lpr/lpr* mice. Furthermore, on the basis of the results of increased IL-2R expression and anti-CD3 mAb response, *lpr*-derived mature T cells seem to be activated in vivo.

In the case of MRL/*lpr*  $\rightarrow$  +/+ chimeras, transplantation of fetal liver cells or T cell-depleted BM does not affect the associated GVH-like disease (14), suggesting that mature T cells, which express TCR-CD3 complex at high density and are able to respond to antigen stimulation, are not indispensable to cause *lpr* GVH syndrome. There are two possibilities: (*a*) wasting syndrome is mediated by non-T populations originated from *lpr* BM cells; and (*b*) T cell precursors in *lpr* BM colonize and differentiate in the host thymus to produce harmful mature T cells. We prefer the latter, considering our data that *lpr* BM cells transplanted into nude mice did not

cause wasting or lymphoid aplasia (data not shown). Further, the results presented here suggest an insufficient negative selection event in the *lpr*  $\rightarrow$  AKR chimeras.

A direct approach to analyze the cellular basis of T cell tolerance came from the observation that certain TCR  $V\beta$  domains are strongly correlated with reactivity to particular antigens (31). Such a direct link has been found between the reactivity to the product of  $Mls^a$  allele and TCR  $V\beta 6/V\beta 8.1$  (19, 28) expressed on T cells. In addition, all TCRs using  $V\beta 3$  have been shown to bind to the product of  $Mls-2^a$  (21, 32, 33). Mice expressing  $Mls^a$  or  $Mls^c$  are found to eliminate  $V\beta 6/V\beta 8.1$ - or  $V\beta 3$ -bearing T cells from their mature T cell pool, respectively (19, 28, 31). A bulk of evidence suggests that  $Mls$  tolerance can be transferred by hematopoietic cells.  $V\beta 6^+$  cells are deleted in both  $Mls^a \rightarrow Mls^b$  and  $Mls^b \rightarrow Mls^a$  radiation chimeras (26, 27, 34). Therefore, deletion of  $V\beta 6^+$  cells require the presence of  $Mls^a$  either on BM-derived cells or on irradiated recipient cells. It has also been shown that  $Mls^a$  and I-E requirements can be genetically complemented in radiation BM chimeras, i.e.,  $V\beta 6/V\beta 8.1$  cells are deleted in situations where deletion does not occur in either donor or host genotype alone. For instance,  $V\beta 6/V\beta 8.1$  cells are deleted in a ( $Mls^b$ , I-E<sup>+</sup>)

**Table 2. Vigorous Anti-CD3 Response by LN Cells from MRL/*lpr*→AKR Chimeras**

	Proliferation with anti-CD3			
	None	0.025 ( $\mu\text{g/ml}$ )	0.2 ( $\mu\text{g/ml}$ )	1.6 ( $\mu\text{g/ml}$ )
			<i>cpm</i>	
C3H→AKR*	399 (87)	5,489 (255)	6,863 (77)	9,204 (1,343)
MRL/+→AKR†	896 (285)	4,821 (1,081)	7,427 (1,986)	17,867 (3,439)
MRL/ <i>lpr</i> →AKR‡	5,717 (1,508)	32,804 (1,090)	82,023 (5,106)	115,239 (2,603)
AKR	1,100 (450)	5,810 (308)	16,553 (1,987)	30,568 (2,863)
MRL/+†	487 (150)	ND	8,399 (1,154)	16,709 (2,195)
MRL/ <i>lpr</i> (7 wk)**	437 (323)	ND	3,307 (1,986)	6,314 (1,814)
MRL/ <i>lpr</i> (11 wk)##	556 (443)	ND	1,554 (681)	2,154 (1,081)

The values represent the arithmetic mean ( $\pm$  SEM) of triplicate samples from one of two experiments. Thy-1.1<sup>+</sup> cells are depleted, as described in Materials and Methods to contain <1% Thy-1.1<sup>+</sup> cells.\*-‡§ Percentages of Thy-1.2<sup>+</sup> cells were 60.8,\* 63.5,† 55.7,§ 81.5 (Thy-1.1),|| 83.2,¶ 82.4,\*\* and 87.1,## CD4/CD8 ratios were 3.4,\* 3.9,† 2.7,§ 1.9,|| 1.7,¶ 1.7,\*\* and 1.5,## respectively. MRL/*lpr* (11 wk) contained >40% Thy-1.2<sup>+</sup> CD4<sup>+</sup>CD8<sup>-</sup> cells.

→ (Mls<sup>a</sup>, I-E<sup>-</sup>) chimera (35). On the other hand, when “nonpermissive” I-E or I-E<sup>-</sup> strain was used as a donor, depletion of the V $\beta$ 6/V $\beta$ 8.1 cells is incomplete (21, 34, 35). Thereby, I-E expression on donor cells is both necessary and sufficient to induce clonal deletion of V $\beta$ 6<sup>+</sup> cells in chimeras, irrespective of Mls<sup>a</sup> source. In addition, recent immunohistological experiments revealed that most of medullary Ia<sup>+</sup> cells are of donor origin in the early stage of BM chimeras (36). Collectively, it is highly likely that donor BM-derived APC in the host thymus are responsible for inducing clonal deletion.

A mechanism of deletion escape in MRL/*lpr* → AKR chimeras should be discussed. As mentioned in Results, two possibilities were postulated: (a) T cell precursors that express *lpr* gene products neglect deletion signals from APC; and (b) APC derived from *lpr* inocula cannot induce sufficient clonal deletion. Results from mixed chimeras suggested that normal Mls<sup>a</sup> APC have an ability to induce clonal deletion to *lpr*-derived T cells, negating the first idea. Recent studies reported that clonal deletion of potential self-reactive cells does occur in untreated *lpr* mice (37, 38). Kotzin et al. (38) have shown that T cells in AKR-*lpr/lpr* mice have undergone a clonal elimination of V $\beta$ 8.1<sup>+</sup> cells. The disparity between their findings of clonal deletion on untreated *lpr* mice and our data on *lpr* → AKR chimeras may be explained as follows. AKR mice homozygous for the *lpr* gene contain cells coexpressing products encoded by Mls<sup>a</sup> and MHC class II

genes that induce clonal deletion of Mls<sup>a</sup>-reactive T cells in the *lpr* thymus without presenting transferable Mls<sup>a</sup> in association with self-MHC molecules. On the other hand, as described above, in Mls<sup>b</sup> → Mls<sup>a</sup> chimeras, host-derived Mls<sup>a</sup> molecules have to be transferred to donor APC to induce clonal deletion of V $\beta$ 6/V $\beta$ 8.1<sup>+</sup> cells. It is likely that APC derived from *lpr* BM may have a deficit in presenting exogenous Mls<sup>a</sup> antigen in association with self-MHC molecules. Although there are several lines of evidence for abnormality in APC in *lpr* mice (39–41), to our knowledge, our data appear to show the first evidence that APC derived from *lpr* BM are deficient in tolerance-related antigen presenting ability.

Schneider et al. (42) demonstrated that CD4<sup>+</sup> V $\beta$ 6<sup>+</sup> cells are present during the early postnatal period in the thymus of Mls<sup>a</sup> mice. If self-reactive T cells develop preferentially in the early stage of T cell ontogeny, thymectomy at early life may bring a relative increase of forbidden self-reactive cells. As for neonatally thymectomized mice, there are reports of appearance of potentially self-reactive T cells that were deleted in the adult thymus (43, and our observations) and development of organ-specific autoimmune disease (44, 45). As shown in Table 1, V $\beta$ 6 expression in MRL/*lpr* → AKR and C3H/*lpr* → AKR CD4<sup>+</sup> T cells seems to be decreased with time after BM transplantation. There remains a possibility that clonal deletion is more “delayed” in these chimeras, as in a neonate, than in their controls.

To elucidate whether failure of V $\beta$ 6 deletion is unique or

one of generalized failure to delete self-reactive cells, we performed additional experiments of MRL  $\rightarrow$  C3H(Mls-2<sup>a</sup>) chimeric combination. However, there was no significant difference between MRL/*lpr*  $\rightarrow$  C3H and MRL/+  $\rightarrow$  C3H in degree of clonal deletion of V $\beta$ 3<sup>+</sup> cells. Several explanations for disparity between MRL  $\rightarrow$  AKR and MRL  $\rightarrow$  C3H chimeras are presumed as: (a) *lpr*-derived T cells are relatively susceptible to Mls<sup>c</sup>-deleting allele; (b) *lpr*-derived APC can present Mls<sup>c</sup> products, but not Mls<sup>a</sup>; and (c) thymic APC of C3H are comparatively radioresistant and there are enough to delete *lpr*-derived V $\beta$ 3<sup>+</sup> cells. Whatever the reason is, high susceptibility of V $\beta$ 3<sup>+</sup> cells MRL/*lpr*  $\rightarrow$  C3H may account for our observation that *lpr*-associated wasting and decrease of peripheral lymphoid cellularity was less serious in the C3H host than in the AKR host.

In spite of occurrence of clonal deletion of V $\beta$ 6<sup>+</sup> cells, progressive lymphoid atrophy was also observed in (MRL/*lpr* + AKR)  $\rightarrow$  AKR mixed chimeras, as previously reported by Perkins et al. (46), indicating that a mere defect in clonal deletion is not sufficient to explain the pathology of *lpr*  $\rightarrow$  non-*lpr* chimeras. High incidence of IL-2R<sup>+</sup> cells in mature T cells of MRL/*lpr*  $\rightarrow$  AKR chimeras is another point to be discussed. Particularly in the "forbidden" V $\beta$ 6<sup>+</sup> thymocytes in *lpr*  $\rightarrow$  AKR chimeras, nearly 40% was IL-2R<sup>+</sup>. Although the V $\beta$ 3<sup>+</sup> subset, which is not a "forbidden" clone, seen in *lpr*  $\rightarrow$  AKR chimeras also contained more IL-2R<sup>+</sup> cells than MRL/+  $\rightarrow$  AKR chimeras, the percentage was lower than the V $\beta$ 6<sup>+</sup> subset of the identical individuals. Since we use 7D4 as anti-IL-2R antibody, which detects only the  $\alpha$  chain of the IL-2R, it may not be concluded that this reflects functional IL-2R on T cells. However, Butler et al.

(47) reported that the kinetics of expression of the IL-2R(7D4) closely correlates with antigen sensitization and proliferative response in vivo, and that tolerance induction or treatment with immunosuppressive drugs reduce IL-2R<sup>+</sup> cells at the population level. Therefore, it could be reasonable to use IL-2R(7D4) expression as an index of cell activation in vivo.

Although, at present, we cannot define what the *lpr*-derived T cells recognize, it is likely that mature T cells not undergoing clonal deletion recognize host antigen and proliferate in MRL/*lpr*  $\rightarrow$  AKR chimeras. Recently, Ramsdell et al. (48) have shown that some combinations of BM chimeras like SJL(Mls-1<sup>b</sup>,H-2<sup>a</sup>)  $\rightarrow$  (B10.S  $\times$  AKR)F<sub>1</sub> (Mls-1<sup>a,b</sup>,H-2<sup>k,s</sup>) do not cause clonal deletion of V $\beta$ 6<sup>+</sup> cells. In spite of containing "forbidden" V $\beta$ 6<sup>+</sup> cells, mature T cells in these chimeras were tolerant to host antigens as a consequence of probable clonal anergy. Turning to the case of MRL/*lpr*  $\rightarrow$  AKR chimeras, from high anti-CD3 response, it may be considered that clonal anergy or suppressor mechanism are also disordered, as well as the clonal deletion mechanism. Mature T cells generated in MRL/*lpr*  $\rightarrow$  AKR chimeras were spontaneously proliferating (Table 2) but decreasing in number. Their features are quite different from accumulated *lpr* LN cells, which exhibit a profound defect in proliferation, IL-2 production, IL-2R expression (49-51), and anti-CD3 mAb responsiveness (52). Both the non-*lpr* thymic environment (including *lpr*-derived APC) and an intrinsic defect of *lpr* T cells may increase such activated T cells, which may contribute to subsequent manifestation of GVHD-like syndrome. Although the main target of the activated T cells remains to be identified, the *lpr*  $\rightarrow$  non-*lpr* BM chimeras seem to be an interesting model for understanding of self-tolerance.

---

We thank Dr. H. Hengartner for generously providing the anti-V $\beta$ 6 mAb (clone 44-22-1), Dr. P. Marrack for the anti-V $\beta$ 8 mAb (clone KJ16 -133), and Dr. J.A. Bluestone for anti-CD3 mAb (clone 145-2C11).

This work was supported in part by grants to Y. Yoshikai from the Ministry of Education, Science and Culture.

Address correspondence to Dr. Koji Matsumoto, Department of Immunology, Medical Institute of Bioregulation, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812, Japan.

Received for publication 23 July 1990.

## References

- Andrews, B.S., R.A. Eisenberg, A.N. Theofilopoulos, S. Izui, C.B. Wilson, P.J. McConahey, E.D. Murphy, J.B. Roths, and F.J. Dixon. 1978. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. *J. Exp. Med.* 148:1198.
- Theofilopoulos, A.N., and F.J. Dixon. 1985. Murine models of systemic lupus erythematosus. *Adv. Immunol.* 37:269.
- Lewis, D.E., J.V. Giorgi, and N.L. Walner. 1981. Flow cytometric analysis of T cells and continuous T-cell lines from autoimmune MRL/1 mice. *Nature (Lond.)* 289:298.
- Morse, H.C., III, W.F. Davidson, R.A. Yetter, E.D. Murphy, J.B. Roths, and R.B. Coffman. 1982. Abnormalities induced by the mutant gene *lpr*: expansion of a unique lymphocyte subset. *J. Immunol.* 129:2612.
- Wofsy, D., R.R. Hardy, and W.E. Seaman. 1984. The proliferating cells in autoimmune MRL/*lpr* mice lack L3T4, antigen on helper T cells that is involved in the response to class II major histocompatibility antigens. *J. Immunol.* 132:2686.
- Nenazee, D.A., S. Studer, M. Steinmetz, Z. Dembic, and M. Kiefer. 1985. The lymphoproliferating cells of MRL/*lpr/lpr* mice are a polyclonal population that bear the T lymphocyte receptor antigen. *Eur. J. Immunol.* 15:760.
- Budd, R.C., M. Schreyer, G.C. Miescher, and H.R. MacDonald. 1988. T cell lineage in the thymus of *lpr/lpr* mice.



- J. Immunol.* 139:2200.
8. Steinberg, A.D., J.B. Roths, E.D. Murphy, R.T. Steinberg, and E.S. Raveche. 1980. Effects of thymectomy or androgen administration upon the autoimmune disease of MRL/Mp-*lpr/lpr* mice. *J. Immunol.* 125:871.
  9. Hang, L., A.N. Theofilopoulos, R.S. Balderas, S.J. Francis, and F.J. Dixon. 1984. The effect of thymectomy on lupus-prone mice. *J. Immunol.* 132:1809.
  10. Theofilopoulos, A.N., R.S. Balderas, D.L. Shawler, S. Lee, and F.J. Dixon. 1981. Influence of thymic genotype on the systemic lupus erythematosus-like disease and T cell proliferation of MRL/Mp-*lpr/lpr* mice. *J. Exp. Med.* 153:1405.
  11. Theofilopoulos, A.N. 1982. Role of the thymus in murine lupus and cellular transfer of the disease. *Arthritis Rheum.* 25:726.
  12. Ikehara, S., R.A. Good, T. Nakamura, K. Sekita, S. Inoue, M. Oo, E. Muso, K. Ogawa, and Y. Hamashima. 1985. Rationale for bone marrow transplantation in the treatment of autoimmune diseases. *Proc. Natl. Acad. Sci. USA.* 82:2483.
  13. Katagiri, T., P.L. Cohen, and R.A. Eisenberg. 1989. The *lpr* gene causes an intrinsic T cell abnormality that is required for hyperproliferation. *J. Exp. Med.* 167:741.
  14. Theofilopoulos, A.N., R.S. Balderas, Y. Gozes, M.T. Aguado, L. Hang, P.R. Morrow, and F.J. Dixon. 1985. Association of *lpr* gene with graft-vs.-host disease-like syndrome. *J. Exp. Med.* 162:1.
  15. Fujiwara, K., and A. Kariyone. 1984. One way occurrence of graft-vs.-host disease in bone marrow chimaeras between congenic MRL mice. *Immunology.* 53:251.
  16. Onoe, K., G. Fernandes, and R.A. Good. 1980. Humoral and cell-mediated immune responses in fully allogeneic bone marrow chimera in mice. *J. Exp. Med.* 151:115.
  17. Sprent, J., D. Lo, E. Gao, and Y. Ron. 1988. T cell selection in the thymus. *Immunol. Rev.* 101:173.
  18. Matsumoto, K., Y. Yoshikai, G. Matsuzaki, T. Asano, and K. Nomoto. 1989. A novel CD3<sup>-</sup>J11d<sup>+</sup> subset of CD4<sup>+</sup>CD8<sup>-</sup> cells repopulating thymus in radiation bone marrow chimeras. *Eur. J. Immunol.* 19:1203.
  19. MacDonald, H.R., R. Schneider, K. Lees, C. Howe, H. Achar-Orbea, H. Festenstein, R.M. Zinkernagel, and H. Hengartner. 1988. T cell receptor V $\beta$  use predicts reactivity and tolerance to Mls<sup>a</sup> encoded antigens. *Nature (Lond.)* 332:40.
  20. Haskins, K., C. Hannum, J. White, N. Roehm, R. Kubo, J. Kappler, and P. Murrack. 1984. The major histocompatibility complex-restricted antigen receptor on T cells. An antibody to a receptor allotype. *J. Exp. Med.* 160:452.
  21. Pullen, A.M., P. Murrack, and J.W. Kappler. 1988. The T-cell repertoire is heavily influenced by tolerance to polymorphic self-antigens. *Nature (Lond.)* 335:796.
  22. Ortega, G.R., R.J. Robb, E.M. Shevach, and T.R. Malek. 1984. The murine IL-2 receptor. I. Monoclonal antibodies that define distinct functional epitopes on activated T cells and react with activated B cells. *J. Immunol.* 139:2200.
  23. Fowlkes, B.J., R.H. Schwartz, and D.M. Pardoll. 1988. Deletion of self-reactive thymocytes occurs at a CD4<sup>+</sup>8<sup>+</sup> precursor stage. *Nature (Lond.)* 334:620.
  24. Macdonald, H.R., H. Hengartner, and T. Pedrazzini. 1988. Intrathymic deletion of self-reactive cells prevented by neonatal anti-CD4 antibody treatment. *Nature (Lond.)* 335:174.
  25. Hengartner, H., B. Odermatt, R. Schneider, M. Schreyer, G. Wille, H.R. MacDonald, and R.M. Zinkernagel. Deletion of self-reactive T cells before entry into the thymus medulla. *Nature (Lond.)* 336:388.
  26. MacDonald, H.R., A.L. Glasebrook, R. Schneider, R.K. Lees, H. Pircher, T. Pedrazzini, O. Kanagawa, J.F. Nicholas, R.C. Howe, R.M. Zinkernagel, and H. Hengartner. 1989. T-cells reactivity and tolerance Mls<sup>a</sup>-encoded antigens. *Immunol. Rev.* 107:89.
  27. Ogimoto, M., Y. Yoshikai, G. Matsuzaki, S. Ohga, K. Matsumoto, and K. Nomoto. 1990. Clonal deletion of self-Mls-reactive thymocytes at the early stage in H-2-compatible but Mls-disparate radiation chimeras. *Immunology.* 69:482.
  28. Kappler, J.W., U. Staerz, J. White, and P.C. Murrack. 1988. Self-tolerance eliminates T cells specific for Mls-modified products of the major histocompatibility complex. *Nature (Lond.)* 332:35.
  29. Uchiyama, T., S. Broder, and T.A. Waldmann. 1980. A monoclonal antibody anti-Tac reactive with activated and functionally mature human T cells. *J. Immunol.* 126:1393.
  30. Roberts, J.L., S. Sharrow, and A. Singer. 1990. Clonal deletion and clonal anergy in the thymus induced by cellular elements with different radiation sensitivities. *J. Exp. Med.* 171:935.
  31. Kappler, J.W., N. Roehm, and P.C. Murrack. 1988. T cell tolerance by clonal elimination in the thymus. *Cell.* 49:273.
  32. Abe, R., S. Vacchio, B. Vox, and R.J. Hodes. 1988. Preferential expression of the T-cell receptor V $\beta$ 3 gene by Mls<sup>a</sup> reactive T cells. *Nature (Lond.)* 335:827.
  33. Fry, A.M., and L.A. Matis. 1988. Self-tolerance alters T-cell receptor expression in antigen-specific MHC restricted immune response. *Nature (Lond.)* 335:830.
  34. Speiser, D.E., R. Schneider, H. Hengartner, H.R. MacDonald, and R.M. Zinkernagel. 1989. Clonal deletion of self-reactive T cells in irradiation bone marrow chimeras and neonatally tolerant mice. *J. Exp. Med.* 170:595.
  35. Speiser, D.E., R.K. Lees, H. Hengartner, H.R. MacDonald, and R.M. Zinkernagel. 1989. Positive and negative selection of T cell receptor V $\beta$  domains controlled by distinct cell populations in the thymus. *J. Exp. Med.* 170:2165.
  36. Wang, B., N. Fukushi, H. Arase, and K. Onoe. 1989. Sites and kinetics for T cell selection. *Proc. Jpn. Soc. Immunol.* 19:112.
  37. Singer, P.A., R.S. Balderas, R.J. McEvilly, M. Bobardt, and A.N. Theofilopoulos. 1989. Tolerance-related V $\beta$  clonal deletions in normal CD4<sup>-</sup>8<sup>-</sup>, TCR- $\alpha/\beta$ <sup>+</sup> and abnormal *lpr* and *gld* cell populations. *J. Exp. Med.* 170:1869.
  38. Kotzin, B.L., S.K. Babcock, and L.R. Heron. 1988. Deletion of potentially self-reactive T cell receptor specificities in L3T4<sup>-</sup>, Lyt2<sup>-</sup> T cells of *lpr* mice. *J. Exp. Med.* 167:1713.
  39. Yamashita, U. 1986. Dysfunction of Ia-positive antigen presenting cells in autoimmune mice. *Cell. Immunol.* 97:257.
  40. Ron, Y., N. Isakov, and J. Sprent. 1987. Unresponsiveness of MRL/MP-*lpr/lpr* mice to antigen given subcutaneously in adjuvant: partial restoration of response after local injection of B cells. *J. Immunol.* 139:400.
  41. Cronin, P.S., A.P. Sing, L.H. Glimcher, V.E. Kelley, and C.L. Reinisch. 1984. The isolation and functional characterization of autoimmune clones expressing inappropriate Ia. *J. Immunol.* 133:822.
  42. Schneider, R., R. Lees, T. Pedrazzini, R.M. Zinkernagel, H. Hengartner, and H.R. MacDonald. 1989. Postnatal disappearance of self-reactive (V $\beta$ 6<sup>+</sup>) cells from the thymus of Mls<sup>a</sup> mice: implication for T cell development and autoimmunity. *J. Exp. Med.* 169:2149.
  43. Smith, H., I.M. Chen, R. Kubo, and K. Tung. 1989. Neonatal thymectomy results in a repertoire enriched in T cells deleted in adult thymus. *Science (Wash. DC)* 245:749.
  44. Nishizuka, Y., and T. Sasakura. 1969. Thymus and reproduction: sex-linked dysgenesis of the gonad after neonatal thymec-

- tomy in mice. *Science (Wash. DC)*. 166:753.
45. Taguchi, O., and Y. Nishizawa. 1980. Autoimmune oophoritis in thymectomized mice: T cell requirement in adoptive cell transfer. *Clin. Exp. Immunol.* 42:324, 1980.
  46. Perkins, D.L., J. Michaelson, R.M. Glaser, and A. Marshak-Rothstein. 1987. Selective elimination of non-*lpr* lymphoid cells in mice undergoing *lpr*-mediated graft-vs.-host disease. *J. Immunol.* 139:1406.
  47. Butler, L.D., P.E. DeRiso, P. Marder, and M.E. Scheetz. 1987. In vivo expression and regulation of murine IL2 receptors after antigen sensitization. *J. Immunol.* 138:470.
  48. Ramsdell, F., T. Lantz, and B.J. Fowlkes. 1989. A nondeletional mechanism of thymic self tolerance. *Science (Wash. DC)*. 246:1038.
  49. Altman, A., N.A. Theofilopoulos, R. Weiner, D.H. Katz, and F.J. Dixon. 1981. Analysis of T cell function in autoimmune murine strains. Defects in production of and responsiveness to interleukin 2. *J. Exp. Med.* 154:791.
  50. Wofsy, D., E.D. Murphy, J.B. Roths, J.M. Dauphinee, S.B. Kipper, and N. Talal. 1981. Deficient interleukin 2 activity in MRL/Mp and C57BL/6J mice bearing the *lpr* gene. *J. Exp. Med.* 154:1671.
  51. Asano, T., K. Himeno, S. Tomooka, B.A. Serushago, and K. Nomoto. 1988. A new T cell subset expressing B220 and CD4 in *lpr* mice: defects in the response to mitogens and in the production of IL-2. *Clin. Exp. Med.* 74:36.
  52. Davignon, J., P.L. Cohen, and R.A. Eisenberg. 1988. Rapid T cell receptor modulation accompanies lack of in vitro mitogenic responsiveness of double negative T cells to anti-CD3 monoclonal antibody in MRL/Mp-*lpr/lpr* mice. *J. Immunol.* 141:1848.